{"nctId":"NCT00468559","briefTitle":"Phase 3/Safety & Efficacy of Esomeprazole in Infants","startDateStruct":{"date":"2007-04"},"conditions":["Gastroesophageal Reflux Disease (GERD)"],"count":98,"armGroups":[{"label":"Open Label Esomeprazole","type":"EXPERIMENTAL","interventionNames":["Drug: Open Label Run In Esomeprazole"]},{"label":"Double Blind Esomeprazole","type":"EXPERIMENTAL","interventionNames":["Drug: Double Blind Esomeprazole"]},{"label":"Double Blind Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Double Blind Placebo"]}],"interventions":[{"name":"Open Label Run In Esomeprazole","otherNames":[]},{"name":"Double Blind Esomeprazole","otherNames":[]},{"name":"Double Blind Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients' parents must sign the informed consent prior to the beginning of any study-related procedures (according to local regulations)\n* patients must have symptoms at study entry and have a clinical diagnosis of suspected GERD, symptomatic GERD, or GERD proven by a test called an endoscopy, a test using a long tube inserted in the body for diagnostic exams\n\nExclusion Criteria:\n\n* patients who have used a PPI (proton pump inhibitors; used to reduce the amount of acid in the stomach) within 7 days before enrollment in the open label treatment phase (Day 0)\n* patients with a history of acute life-threatening event","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"11 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint)","description":"Number of participants discontinuing during the 4-week of randomized double-blind withdrawal phase that met the pre-set definition of symptom worsening criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Discontinuing Due to Any Reason, Including Symptom Worsening, in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint)","description":"Number of participants discontinuing due to any reason was identical to the number of participants discontinuing due to symptom worsening (the primary assessment) when no participants discontinued due to reason other than symptom worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Successes at the End of the 4-week Double-blind Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint).","description":"The number of participants reaching the end of the treatment withdrawal phase without discontinuing from the study (for any reason) or showing symptom worsening in the physician global assessment of Gastroesophageal Reflux Disease (GERD) symptoms. Based on the severity of symptoms reported by the parent/guardian in IVRS, the investigator provided the overall clinical impression of the patient's GERD-related symptoms over the last 7 days as:\n\nNone Mild Moderate Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment (PGA) of Gastroesophageal Reflux Disease (GERD) Symptoms (Treatment Withdrawal Phase Endpoint)","description":"Percentage of participants with Physician's Global Assessment (PGA) score at the final treatment withdrawal assessment in following categories: None (no symptoms), Mild, Moderate or Severe. The worst post-randomization Physician's Global Assessment (PGA) assessment during double blind phase is taken into account.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null},{"groupId":"OG001","value":"48.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Vomiting/Regurgitation Symptoms as Reported by the Parent/Guardian (Treatment Withdrawal Phase Endpoint)","description":"Change from baseline in symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.040","spread":"0.560"},{"groupId":"OG001","value":"0.090","spread":"0.610"}]}]}]},{"type":"SECONDARY","title":"Severity of Irritability Crying/Fussing Symptoms as Reported by the Parent/Guardian (Treatment Withdrawal Phase Endpoint)","description":"Change from baseline in symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.060","spread":"0.580"},{"groupId":"OG001","value":"0.190","spread":"0.590"}]}]}]},{"type":"SECONDARY","title":"Severity of Supraesophageal/Respiratory Disturbances (Coughing/Wheezing,Labored Breathing) as Reported by Parent/Guardian (Treatment Withdrawal Phase Endpoint)","description":"Change from baseline in symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.120","spread":"0.480"},{"groupId":"OG001","value":"0.030","spread":"0.580"}]}]}]},{"type":"SECONDARY","title":"Severity of Feeding Difficulties Reported by Parent/Guardian (Treatment Withdrawal Phase Endpoint)","description":"Change from baseline in symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.090","spread":"0.480"},{"groupId":"OG001","value":"0.100","spread":"0.610"}]}]}]},{"type":"SECONDARY","title":"Improvement in Physician's Global Assessment (PGA) Following Open-label Esomeprazole (Open-label Phase Endpoint)","description":"Number of patients who had an improvement of at least one category in the PGA at the end of open-label treatment with esomeprazole compared to baseline. Improvement in PGA was a pre-requisite for randomization into the randomized treatment withdrawal phase. Only patients with PGA at baseline and end of open-label are analyzed here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Vomiting/Regurgitation Symptoms as Reported by the Parent/Guardian (Open-label Phase)","description":"Symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, The score is the mean severity in each 7-day period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Severity of Irritability Crying/Fussing Symptoms as Reported by the Parent/Guardian (Open-label Phase Endpoint)","description":"Symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, The score is the mean severity in each 7-day period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Severity of Supraesophageal/Respiratory Disturbances (Coughing/Wheezing,Labored Breathing) as Reported by Parent/Guardian (Open-label Phase Endpoint)","description":"Symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, The score is the mean severity in each 7-day period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.69"}]}]}]},{"type":"SECONDARY","title":"Severity of Feeding Difficulties as Reported by Parent/Guardian (Open-label Phase Endpoint)","description":"Symptom severity (Severity is scored as 0-4 \\[none, mild moderate, severe\\]). For each participant, The score is the mean severity in each 7-day period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.76"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":98},"commonTop":["Upper Respiratory Tract Infection","Pyrexia","Cough","Rhinitis","Bronchitis"]}}}